Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Prostate cancer

New Platinum Complex Shows Promise in Treating Advanced Prostate Cancer

A recent study published in Inorganic Chemistry reveals a promising new approach to prostate cancer treatment using azolato-bridged dinuclear platinum(II) complexes. Led by researchers from Shibaura Institute of Technology, the study highlights the potential of the compound 5-H-Y to effectively target prostate cancer cells with reduced toxicity compared to traditional cisplatin. This innovative therapy could transform treatment options for advanced prostate cancer patients, offering hope for improved outcomes and minimized side effects.

Expert Panel Highlights Importance of Patient Engagement in Advanced Prostate Cancer Care

A recent expert panel on advanced prostate cancer highlighted the importance of patient education, early detection, and open communication with healthcare providers. They emphasized proactive engagement in treatment decisions and the benefits of a multidisciplinary approach to care. Understanding treatment options like hormone therapy and the role of PSA testing can empower patients and enhance their quality of life.

Promising Study Aims to Reduce Radiation Treatments for Prostate Cancer

A groundbreaking study at The Davidoff Comprehensive Cancer Center aims to reduce radiation treatments for prostate cancer from five to two, enhancing patient care and outcomes. Prostate cancer, prevalent among men, could see improved management through this innovative approach, potentially transforming treatment protocols globally.

Study Links Pesticide Exposure to Increased Prostate Cancer Risk

Recent research from Stanford University reveals a troubling link between pesticide exposure and prostate cancer, identifying 22 pesticides that may increase risk. This groundbreaking study highlights the potential dangers in common foods and emphasizes the need for consumers to be aware of agricultural practices affecting their health. With prostate cancer affecting one in eight men in the U.S., understanding the implications of pesticide residues in food is crucial for public health.

Transforming Prostate Cancer Treatment: Advances in Hormonal Therapies and Patient-Centric Approaches

The landscape of prostate cancer treatment is evolving with novel hormonal therapies that enhance patient outcomes for both metastatic and nonmetastatic cases. Insights from Dr. Bradley C. Carthon highlight the importance of personalized medicine, therapy sequencing, and patient characteristics in optimizing treatment strategies. As new research emerges, clinicians are better equipped to tailor interventions, improving survival rates and quality of life for patients.

UTEP Researchers Develop Low-Cost Device for Rapid Cancer Detection

Researchers at The University of Texas at El Paso have developed a low-cost portable device that can detect colorectal and prostate cancer in just one hour. This groundbreaking technology aims to enhance cancer diagnosis accessibility, especially in developing countries, by providing rapid and accurate results without the need for expensive equipment. The innovative biochip device captures cancer biomarkers using a unique microfluidic design, making early detection more feasible and potentially saving lives.

Revolutionizing Prostate Cancer Diagnosis with PSMA-PET Imaging

Discover the future of prostate cancer diagnosis with PSMA-PET imaging, as Dr. Brian T. Helfand highlights advancements in imaging technologies that promise earlier detection and personalized treatment strategies. Learn how innovative radiotracers and a deeper understanding of tumor biology are set to revolutionize urologic oncology.

Metformin May Reduce Prostate Cancer Risk, New Meta-Analysis Finds

Recent studies suggest that metformin, a diabetes medication, may reduce the risk of prostate cancer. A meta-analysis found that metformin users had a lower incidence of prostate cancer. While metformin did not significantly impact cancer recurrence or mortality rates, its effectiveness varied based on study type and geographic population. The duration of metformin use also played a role in its protective effects against prostate cancer.

New Prevention Strategies Urgently Needed for Prostate Cancer

Prostate cancer research reveals the significant impact of genetic risk and lifestyle factors on early and late prostate cancer death rates. A recent study involving over 19,000 men found a 3-fold increased risk of early death for those at higher genetic risk. Lifestyle choices such as smoking and obesity were also linked to higher risk. Targeted prevention strategies focusing on healthy lifestyle behaviors could potentially prevent 36% of deaths in the higher genetic risk group. The study underscores the importance of lifestyle modifications in reducing prostate cancer risk among individuals with a genetic predisposition.

Study Raises Concerns About Prostate Cancer Screening in Transgender Women

A recent study led by the University of California – San Francisco has raised concerns about the interpretation of standard prostate cancer screening guidelines for transgender women. Transgender women on hormone therapy may show artificially low results on PSA tests, potentially delaying the detection and treatment of prostate cancer. Specific PSA ranges tailored to this population are needed to address the unique challenges faced by transgender women in prostate cancer screening.